Tricyclo[3.3.1.13,7]decan-1-amine,3,5-dimethyl-

MF: C₁₂H₂₁N
Density: 1.046 g/cm³
Flash Point: 92.3 °C
MW: 179.301840 g/mol
Product Name: Memantine
IUPAC: 3,5-dimethyladamantan-1-amine
Boiling Point: 239.8 °C at 760 mmHg
Enthalpy of Vaporization: 47.67 kJ/mol
Vapour Pressure: 0.0393 mmHg at 25°C 
Synonyms: AKOS BB-9600 ; MEMANTINE ; AURORA KA-7643 ; TIMTEC-BB SBB002574 ; 3,5-dimethyladamantan-1-amine HCl ; 1-Amino-3,5-dimethyladamantane ; 3,5-Dimethyl-1-aminoadamantane ; 3,5-DIMETHYL-1-AMINOADAMANTANE( MEMANTINE )
Following is the molecular structure of Memantine (19982-08-2):









 

Memantine was first synthesized and patented by Eli Lilly and Company in 1968 (as cited in the Merck Index), and then developed by Merz  in collaboration with Neurobiological Technologies, Inc. and licensed to Forest for the U.S. and Lundbeck for selected European and international markets.

Memantine has been associated with a moderate decrease in clinical deterioration in Alzheimer's disease.A systematic review of randomised controlled trials found that memantine has a small positive effect on cognition, mood, behaviour, and the ability to perform daily activities in moderate to severe Alzheimer's disease, but an unknown effect in mild to moderate disease.
Memantine is also being tested for opioid dependence, systemic lupus erythematosus, depression, obsessive compulsive disorder, Tourette Syndrome, problem gambling, attention-deficit hyperactivity disorder (ADHD),glaucoma, tinnitus, neuropathic pain including Complex Regional Pain Syndrome, pervasive developmental disorders, HIV associated dementia, nystagmus, and multiple sclerosis.

Safety Information of Memantine (19982-08-2):
Hazard Codes : Xi
Xi : Irritant
Safety Statements  24/25 ( Avoid contact with skin and eyes  )
Hazardous Substances Data: 19982-08-2(Hazardous Substances Data)